Tags

Type your tag names separated by a space and hit enter

A RETROSPECTIVE STUDY EXAMINING PHENTERMINE ON PRECONCEPTION WEIGHT LOSS AND PREGNANCY OUTCOMES.
Endocr Pract. 2020 May 14 [Online ahead of print]EP

Abstract

Background:

Obesity is a well-known risk factor for infertility. However, use of weight loss medications prior to conception is underutilized. The objectives of our study are to describe weight loss, pregnancy rates, and live birth rates after short-term phentermine use in women with obesity and infertility.

Methods:

This was a retrospective analysis of 55 women (18-45 years old) who were overweight or obese, diagnosed with infertility, and prescribed phentermine for weight loss in an ambulatory endocrinology clinic at a single, tertiary level academic medical center. Main outcome measures were mean percent weight change at 3 months after starting phentermine and pregnancy and live birth rates from start of phentermine to June 30, 2017.

Results:

Median duration of phentermine use was 70 days (Q1, Q3 [33, 129]). Mean ± SD percent weight change at 3 months after starting phentermine was -5.3 ± 4.1% (p < 0.001). The pregnancy rate was 60% and live birth rate was 49%. There was no significant difference in pregnancy rates (52% vs. 68%, p = 0.23) or live birth rates (44% vs. 54%, p = 0.50) in women who lost ≥5% vs. <5% of their baseline weight. Number of metabolic comorbidities was negatively associated with pregnancy rate. Phentermine was generally well tolerated with no serious adverse events.

Conclusions:

Phentermine can produce clinically significant weight loss in women with obesity during the preconception period. Higher pregnancy or live birth rates were not observed with greater degree of weight loss with phentermine.

Authors+Show Affiliations

From: Division of Endocrinology, Gerontology, and Metabolism, Department of Medicine, 300 Pasteur Drive, Grant S025, Stanford, California, USA.Division of Reproductive Endocrinology and Infertility, Department of Obstetrics and Gynecology, Stanford Health Care, 1195 W. Fremont Avenue, Sunnyvale, California, USA.From: Division of Endocrinology, Gerontology, and Metabolism, Department of Medicine, 300 Pasteur Drive, Grant S025, Stanford, California, USA. Stanford Diabetes Research Center, Division of Endocrinology, Gerontology, and Metabolism, Department of Medicine, 300 Pasteur Drive, Stanford, California, USA.

Pub Type(s)

Journal Article

Language

eng

PubMed ID

32407664

Citation

Chang, Julia J., et al. "A RETROSPECTIVE STUDY EXAMINING PHENTERMINE ON PRECONCEPTION WEIGHT LOSS and PREGNANCY OUTCOMES." Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists, 2020.
Chang JJ, Lathi RB, Kim SH. A RETROSPECTIVE STUDY EXAMINING PHENTERMINE ON PRECONCEPTION WEIGHT LOSS AND PREGNANCY OUTCOMES. Endocr Pract. 2020.
Chang, J. J., Lathi, R. B., & Kim, S. H. (2020). A RETROSPECTIVE STUDY EXAMINING PHENTERMINE ON PRECONCEPTION WEIGHT LOSS AND PREGNANCY OUTCOMES. Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists. https://doi.org/10.4158/EP-2019-0609
Chang JJ, Lathi RB, Kim SH. A RETROSPECTIVE STUDY EXAMINING PHENTERMINE ON PRECONCEPTION WEIGHT LOSS and PREGNANCY OUTCOMES. Endocr Pract. 2020 May 14; PubMed PMID: 32407664.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - A RETROSPECTIVE STUDY EXAMINING PHENTERMINE ON PRECONCEPTION WEIGHT LOSS AND PREGNANCY OUTCOMES. AU - Chang,Julia J, AU - Lathi,Ruth B, AU - Kim,Sun H, Y1 - 2020/05/14/ PY - 2020/5/15/entrez PY - 2020/5/15/pubmed PY - 2020/5/15/medline KW - infertility KW - obesity KW - phentermine KW - preconception weight loss JF - Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists JO - Endocr Pract N2 - Background: Obesity is a well-known risk factor for infertility. However, use of weight loss medications prior to conception is underutilized. The objectives of our study are to describe weight loss, pregnancy rates, and live birth rates after short-term phentermine use in women with obesity and infertility. Methods: This was a retrospective analysis of 55 women (18-45 years old) who were overweight or obese, diagnosed with infertility, and prescribed phentermine for weight loss in an ambulatory endocrinology clinic at a single, tertiary level academic medical center. Main outcome measures were mean percent weight change at 3 months after starting phentermine and pregnancy and live birth rates from start of phentermine to June 30, 2017. Results: Median duration of phentermine use was 70 days (Q1, Q3 [33, 129]). Mean ± SD percent weight change at 3 months after starting phentermine was -5.3 ± 4.1% (p < 0.001). The pregnancy rate was 60% and live birth rate was 49%. There was no significant difference in pregnancy rates (52% vs. 68%, p = 0.23) or live birth rates (44% vs. 54%, p = 0.50) in women who lost ≥5% vs. <5% of their baseline weight. Number of metabolic comorbidities was negatively associated with pregnancy rate. Phentermine was generally well tolerated with no serious adverse events. Conclusions: Phentermine can produce clinically significant weight loss in women with obesity during the preconception period. Higher pregnancy or live birth rates were not observed with greater degree of weight loss with phentermine. SN - 1530-891X UR - https://www.unboundmedicine.com/medline/citation/32407664/A_RETROSPECTIVE_STUDY_EXAMINING_PHENTERMINE_ON_PRECONCEPTION_WEIGHT_LOSS_AND_PREGNANCY_OUTCOMES L2 - http://journals.aace.com/doi/10.4158/EP-2019-0609?url_ver=Z39.88-2003&amp;rfr_id=ori:rid:crossref.org&amp;rfr_dat=cr_pub=pubmed DB - PRIME DP - Unbound Medicine ER -
Try the Free App:
Prime PubMed app for iOS iPhone iPad
Prime PubMed app for Android
Prime PubMed is provided
free to individuals by:
Unbound Medicine.